Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2022

Rhea-AI Summary

Enanta Pharmaceuticals plans to report its financial results for the fiscal second quarter ended March 31, 2022, on May 9, 2022. A conference call will follow at 4:30 p.m. ET to discuss results and updates on the company's research pipeline, which focuses on small molecule drugs for viral infections and liver diseases, including targets like RSV, COVID-19, and HBV. Enanta's R&D is funded by royalties from HCV products developed in collaboration with AbbVie, notably Glecaprevir, part of its leading treatment for chronic HCV infections.

Positive

• Enanta's research pipeline includes clinical candidates for RSV, COVID-19, and HBV, indicating a diverse focus on viral infections.
• Funding for R&D through royalties from successful HCV treatments suggests a strong revenue base.

Negative

• None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2022 after the U.S. market closes on May 9, 2022. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta’s business, including its research and development pipeline.

Conference Call and Webcast Information

To participate in the live conference call, please dial 844-467-7101 in the U.S. or 270-215-9353 for international callers. A replay of the conference call will be available starting at approximately 7:30 p.m. ET on May 9, 2022, through 11:59 p.m. ET on May 16, 2022 by dialing 855-859-2056 from the U.S. or 404-537-3406 for international callers. The passcode for both the live call and the replay is 7061969. A live audio webcast of the call and replay can be accessed by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates currently in development for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research in human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220502005130/en/

Media and Investor Contact

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

When will Enanta report its financial results?

Enanta Pharmaceuticals will report its financial results for the fiscal second quarter on May 9, 2022.

What is the focus of Enanta's research and development?

Enanta's R&D focuses on small molecule drugs for viral infections and liver diseases, including RSV, COVID-19, and HBV.

How is Enanta funding its research activities?

Enanta's research and development activities are funded by royalties from hepatitis C virus products developed under its collaboration with AbbVie.

What time is the conference call for Enanta's financial results?

The conference call to discuss Enanta's financial results is scheduled for 4:30 p.m. ET on May 9, 2022.

Where can I access the conference call replay for Enanta?

A replay of Enanta's conference call will be available from 7:30 p.m. ET on May 9, 2022, through 11:59 p.m. ET on May 16, 2022.